<DOC>
	<DOCNO>NCT02607813</DOCNO>
	<brief_summary>A Phase I Study LXH254 Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations .</brief_summary>
	<brief_title>Phase I Study LXH254 Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations</brief_title>
	<detailed_description />
	<criteria>All patient participate clinical trial must progress follow standard therapy , , opinion Investigator , effective standard therapy exist , tolerated appropriate . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Presence least one measurable lesion accord RECIST v1.1 . Documented MAPK alteration Prior treatment BRAFi , MEKi and/or panRAF inihibitors patient enrol group 1 2 dose expansion part . Exceptions may make documented agreement Novartis Investigator . History current evidence retinal vein occlusion ( RVO ) current risk factor RVO . Any medical condition would , investigator 's judgment , prevent patient 's participation clinical study due safety concern compliance clinical study procedure . Patients receive proton pump inhibitor discontinue 3 day prior start study treatment duration study . Pregnant nursing ( lactate ) woman Additional exclusion criterion LXH254 combination PDR001 History severe hypersensitivity reaction , opinion investigator may cause increase risk serious infusion reaction . Known human immunodeficiency virus ( HIV ) . Any positive test hepatitis B virus hepatitis C virus indicate acute chronic infection . Active , know suspected autoimmune disease . Active infection require systemic antibiotic therapy Patients require systemic steroid therapy immunosuppressive therapy ( ≥10mg/day prednisone equivalent ) discontinue least 7 day prior first dose study treatment . Use live vaccine infectious disease within 4 week initiation study treatment . Other inclusion/exclusion criterion per protocol may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>LXH254 , CRAF , MAPK , solid tumor , PDR001</keyword>
</DOC>